3rd ESTRO Forum 2015 S399 General and Biennial meetings and forums from 2004 to 2014 inclusive. Abstracts were individually reviewed and only those with the radiation therapist being the main focus of the abstract were selected. The abstracts were then categorized according to specific themes based on subject matter. Results: In total 14935 abstracts were reviewed and only 46 (0.3%) had the radiation therapist as the main focus. The number of selected abstracts by year ranged from a low of 1 in 2004 to a high of 24 in 2014, with those from 2013 and 2014 combined representing 65% of all selected abstracts. The selected abstracts were classified into the following themes: education (21 of 46), clinical applications (12 of 46), role definition (8 of 46), workplace wellness (3 of 46), and quality of care (2 of 46). Conclusions: Although the roles and responsibilities of radiation therapists are expanding and therapists are being recognized for their knowledge and skills in radiation oncology and cancer care more broadly, our results suggest that this expansion has not been proportionally represented in the radiation oncology literature as only 0.3% of published abstracts had a main focus on the radiation therapist. Encouragingly, however, the number of abstracts has increased substantially during the past 10 years, with the last two years alone far exceeding the preceding years combined. As the profession of the radiation therapist evolves and offers more opportunities for advanced practice qualifications and graduate level education it is expected that research on radiation therapists will increase, and the themes of said research will become more diverse.
Purpose/Objective: SBRT is the standard of care for inoperable patients with early-stage lung cancer without lymph node involvement. Excellent local control rates have been reported in a large number of series. However, prescription doses and calculation algorithms vary to a great extent between studies, even if most teams prescribe on the D95 of the PTV. Type A algorithms are known to produce dosimetric discrepancies in heterogeneous tissues such as lungs. This study was performed to present a MC prescription dose for NSCLC adapted to lesion size and location and compare the clinical outcome of two cohorts of patients treated with a type A algorithm and standard prescription dose or the proposed MC protocols. Materials and Methods: All inoperable patients treated in our institution between August 2007 and April 2013 with SBRT for early-stage lung cancer were included. Treatment planning was performed with a type A algorithm (Ray Tracing, RT) with 3 fractions of 20 Gy for peripheral lesions and 60 Gy in 5 fractions for central lesions prescribed to the PTV D95 until January 2011. A type B algorithm (Monte Carlo, MC) with 54 Gy in 3 fractions for peripheral lesions with a diameter under 30 mm, 60 Gy in 3 fractions for lesions with a diameter over 30 mm and 55 Gy in 5 fractions for central lesions was used for patients treated after this date. All treatment plans were recalculated with both algorithms for this study. Spearman's rank correlation coefficient was calculated for GTV and PTV. Local control, overall survival and toxicity were compared between the two groups Results: 205 patients with 214 lesions were included in the study. 121 lesions were treated with RT and 93 with MC. D50 of the GTV calculated with MC was poorly correlated with the D95 of the PTV calculated with RT (r=0.116) for lesions with a diameter of 20 mm or less. For lesions larger than 20 mm, spearman correlation was higher (r=0.618), but still insufficient. Overall survival rates were 94% and 86% at one and two years respectively. Local control rates were 93% and 79% at one and two years respectively. There was no significant difference between the two groups for overall survival (p=0.785) or local control (p=0.934). 56 patients (27%) presented a grade 1 lung fibrosis without clinical consequences. GTV size was a prognostic factor for overall survival (HR=1.026, IC95% [1.01-1.041], p<0.001) and total dose was a prognostic factor for local control (HR=0.924, IC95% [0.870-0.982], p=0.011).
Conclusions:
The dose calculated with a type A algorithm does not correctly reflect the dose actually received by the tumor. A type B algorithm should be preferred to directly prescribe on the GTV in order to avoid the dose calculation variability created by normal lung tissue found in the GTV to PTV margin. Patients treated with the proposed protocol had the same local control and overall survival rates as patients treated with the type A algorithm.
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Volumetric analysis of MRI response in meninigiomas treated with 3-dimensional conformal radiation therapy C. Kim 1 , N. Lee 1 , W. Yoon 1 , Y. Chung 2 , N. Lee 3 1 Korea University Anam Hospital, Radiation Oncology, Seoul, Korea Republic of 2 Korea University Anam Hospital, Neurosurgery, Seoul, Korea Republic of 3 Korea University Anam Hospital, Radiology, Seoul, Korea Republic of Purpose/Objective: We evaluated sequential magnetic resonance imagings to assess the inherent response of intracranial meningiomas after three-dimensional conformal radiation therapy.
Materials and Methods
Quantitative tumor volume measurements were generated from 126 magnetic resonance images of a total of 26 patients. Both parametric and nonparametric regression analyses were used to assess the relationships of the percentage of tumor volume reduction with the elapsed time after irradiation and the pattern of tumor volume reduction. Results: The median follow-up time was 103.5 months (range, 29.6-137.3 months). The mean pre-radiation therapy tumor volume was 28.60 cm 3 (range, 1.34-167.35 cm 3 ). Tumor volume reduction was observed in 96.2% of the study population. The mean absolute and relative tumor volume reduction were 13.9 cm 3 (range, 0.4-84.5 cm 3 ) and 44.6% (range, 14.7-89.0%), respectively. After irradiation, the tumor volume reduction rate was 8.02% per year. Meningiomas that were ≥40 cm 3 showed a higher rate of
